Published finding — does the expert body still believe it?
The EARLYSTIM trial's stated primary conclusion — Early STN-DBS improves quality of life in Parkinson disease patients with early motor complications vs. medical therapy. — replicates in independent cohorts.
TL;DR · AI-generated
Subthalamic stimulation was superior to medical therapy in patients with Parkinson's disease and early motor complications and time with good mobility and no dyskinesia.
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
2 events · 1 snapshot
posterior drift
71% → 71% (0pp · 1 point)
Registry data
Apr 18, 2026
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Neurostimulation for Parkinson's Disease with Early Motor Complications
W.M.M. Schuepbach et al. · New England Journal of Medicine · 2013
· openalex W2106956384 · s2 cb543cbd
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1839
By 2028, DBS referral in PD will routinely be considered within 5 years of motor-complication onset (vs. the historical ≥10-year pattern).
0.2090
Recent follow-up analyses of EARLYSTIM are confirming the original effect size in real-world data.
0.2453
The NURTURE (nusinersen) trial's stated primary conclusion — Presymptomatic nusinersen in SMA infants preserves motor function milestones in long-term follow-up. — replicates in independent cohorts.
0.2501
The EMERGE (aducanumab) trial's stated primary conclusion — Aducanumab’s pivotal phase 3 showed mixed evidence for cognitive slowing in early Alzheimer disease. — replicates in independent cohorts.
0.2505
The MR CLEAN trial's stated primary conclusion — Endovascular thrombectomy within 6h improves functional outcome in proximal anterior circulation stroke. — replicates in independent cohorts.
0.2512
The ESCAPE trial's stated primary conclusion — Rapid endovascular treatment improves functional outcomes in proximal anterior-circulation stroke. — replicates in independent cohorts.